Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

508
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
508
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

10.4K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
10.4K
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

546
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
546
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

590
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
590
Peripheral Artery Disease IV: Nursing Management01:26

Peripheral Artery Disease IV: Nursing Management

511
 The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
511
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

789
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
789

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence and prognostic value of activated protein C resistance and anti-protein C antibodies in patients with antiphospholipid antibodies: an APS ACTION Registry study.

Rheumatology (Oxford, England)·2026
Same author

Correction: Anti-β2GPI IgG display a broad reactivity against different β2GPI domains beyond domain 1: results from the APS ACTION and multi-center Italian cohorts.

Frontiers in immunology·2026
Same author

Hydroxychloroquine and teratogenic risk in pregnancy in systemic autoimmune diseases: A systematic narrative review.

Autoimmunity reviews·2026
Same author

Anti-β2GPI IgG display a broad reactivity against different β2GPI domains beyond domain 1: results from the APS ACTION and multi-center Italian cohorts.

Frontiers in immunology·2026
Same author

Changing Patterns in Hospitalisations of Patients with Systemic Lupus Erythematosus over Three Decades at a Tertiary Referral Centre in Catalonia.

Journal of clinical medicine·2026
Same author

Hydroxychloroquine as an Adjunct Therapy for Secondary Thrombosis Prevention in Primary Antiphospholipid Syndrome: A Systematic Review and Meta-analysis.

Rheumatology and therapy·2026
Same journal

Apoptotic versus procoagulant platelets: similar "necrotic" phenotype and procoagulant activity in vitro, but distinct adhesive protein composition.

Thrombosis research·2026
Same journal

Heatstroke-induced coagulopathy: A scoping review of therapeutic strategies and outcome reporting.

Thrombosis research·2026
Same journal

Mapping thrombus habitat: Non-contrast MRI radiomics and pixel-tile histomics approach to track venous thrombosis evolution in mice.

Thrombosis research·2026
Same journal

A study protocol for a randomised controlled trial evaluating the safety and efficiency of the YEARS algorithm versus computed tomography pulmonary angiography only for suspected acute pulmonary embolism in patients with cancer: the Hydra Study.

Thrombosis research·2026
Same journal

Associating the phenotypic expression of platelets with disease type through image-based single-cell profiling.

Thrombosis research·2026
Same journal

The mechanisms of contractile dysfunction following chronic limited platelet activation in (pro)thrombotic conditions.

Thrombosis research·2026
See all related articles

Related Experiment Video

Updated: Mar 6, 2026

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2
10:31

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2

Published on: September 26, 2025

581

Antiphospholipid syndrome.

Ricard Cervera1

  • 1Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Catalonia, Spain.

Thrombosis Research
|March 7, 2017
PubMed
Summary
This summary is machine-generated.

Antiphospholipid syndrome (APS) involves blood clots and pregnancy issues due to antiphospholipid antibodies (aPL). Current treatments include anticoagulation for thrombosis and aspirin with heparin for obstetric complications.

Keywords:
Anticardiolipin antibodiesAntiphospholipid syndromeCatastrophic antiphospholipid syndromeLupus anticoagulant

More Related Videos

PIP-on-a-chip: A Label-free Study of Protein-phosphoinositide Interactions
10:58

PIP-on-a-chip: A Label-free Study of Protein-phosphoinositide Interactions

Published on: July 27, 2017

10.0K
Fluorescence-Based Measurements of Phosphatidylserine/Phosphatidylinositol 4-Phosphate Exchange Between Membranes
08:49

Fluorescence-Based Measurements of Phosphatidylserine/Phosphatidylinositol 4-Phosphate Exchange Between Membranes

Published on: March 14, 2021

4.7K

Related Experiment Videos

Last Updated: Mar 6, 2026

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2
10:31

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2

Published on: September 26, 2025

581
PIP-on-a-chip: A Label-free Study of Protein-phosphoinositide Interactions
10:58

PIP-on-a-chip: A Label-free Study of Protein-phosphoinositide Interactions

Published on: July 27, 2017

10.0K
Fluorescence-Based Measurements of Phosphatidylserine/Phosphatidylinositol 4-Phosphate Exchange Between Membranes
08:49

Fluorescence-Based Measurements of Phosphatidylserine/Phosphatidylinositol 4-Phosphate Exchange Between Membranes

Published on: March 14, 2021

4.7K

Area of Science:

  • Immunology
  • Hematology
  • Obstetrics

Background:

  • Antiphospholipid syndrome (APS) is characterized by thrombosis and pregnancy morbidity in the presence of antiphospholipid antibodies (aPL).
  • APS affects approximately 5 in 100,000 individuals annually, with a prevalence of 40-50 per 100,000.
  • Antiphospholipid antibodies are detected in a significant percentage of patients experiencing stroke, myocardial infarction, deep vein thrombosis, and pregnancy complications.

Purpose of the Study:

  • To review the current understanding of the clinical manifestations of antiphospholipid syndrome.
  • To summarize established and emerging therapeutic strategies for managing APS.

Main Methods:

  • This review synthesizes existing medical literature on antiphospholipid syndrome.
  • It focuses on clinical presentations and treatment guidelines.

Main Results:

  • Antiphospholipid syndrome is defined by recurrent thrombotic events and/or specific pregnancy complications.
  • Antiphospholipid antibodies are a key diagnostic marker, found in various vascular and obstetric conditions.

Conclusions:

  • Long-term oral anticoagulation is the standard treatment for APS patients with thrombosis.
  • Aspirin combined with heparin is recommended for preventing obstetric complications in APS.